433958-46-4

Basic information

• Product Name: 2-amino-4-(3-aminophenyl)-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)nicotinonitrile
• Synonyms: 2-amino-4-(3-aminophenyl)-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)nicotinonitrile
• CAS NO: 433958-46-4
• Molecular Weight: 416.598
• Mol File: 433958-46-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-amino-4-(3-aminophenyl)-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)nicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-4-(3-aminophenyl)-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)nicotinonitrile(433958-46-4)
• EPA Substance Registry System: 2-amino-4-(3-aminophenyl)-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)nicotinonitrile(433958-46-4)

Safety Data

• Hazardous Substances Data: 433958-46-4(Hazardous Substances Data)

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 120820-40-8 1-(2-(((1,1-dimethylethyl)dimethylsilyl)oxy)phenyl)ethanone 
• 109-77-3 malononitrile 
• 433958-47-5 2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}-phenyl)-4-(3-nitrophenyl)pyridine-3-carbonitrile 

Downstream Products

• 433958-86-2 N-{3-[2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-cyano-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide 
• 433958-58-8 N-{3-[2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-cyano-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide 
• 433958-64-6 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinonitrile 
• 925922-23-2 N-{3-[2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-cyanopyridin-4-yl]phenyl}-2,2,2-trifluoroacetamide 
• 433957-83-6 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide 
• 433958-84-0 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide hydrochloride 

Relevant articles and documents

PYRIDYLPHENOL COMPOUND AND USE THEREOF

The present invention provides a compound which has metastin receptor antagonist activity and is useful for preventing and treating hormone-dependent cancer, benign prostatomegaly, endometriosis, precocious puberty, uterine myoma or the like. More specifically, the present invention provides a compound, represented by the formula: or a salt thereof, a prodrug thereof, and a pharmaceutical agent containing the same; wherein Ring A represents a 5- to 8-membered homocyclic or heterocyclic group optionally having a substituent other than formula -X-R1 wherein X represents a bond or a spacer, and R1 represents optionally substituted amino or an optionally substituted nitrogen-containing heterocyclic group; Ring B represents an optionally substituted benzene ring; R2 represents an optionally substituted homocyclic or heterocyclic group; and R3 and R4 independently represent a hydrogen atom, cyano, acyl or an optionally substituted hydrocarbon group.

Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1

IκB kinase β (IKK-β) is a serine-threonine protein kinase critically involved in the activation of the transcription factor Nuclear Factor kappa B (NF-κB) in response to various inflammatory stimuli. We have identified a small molecule inhibitor of IKK-β. Optimization of the lead compound resulted in improvements in both in vitro and in vivo potency, and provided IKK-β inhibitors exhibiting potent activity in an acute cytokine release model (LPS-induced TNFα).